Loading cancer entity…
Loading cancer entity…
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors(CYCAD-1) | recruiting | Phase 1 / Phase 2 | 564 | AstraZenecaINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY |
| 3 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT01883297 | "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06976892 | Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer(IDOL) | recruiting | Phase 1 | 33 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials